QTTB Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Q32 Bio

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Q32 Bio

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

4 months ago - By: The Motley Fool

Q32 Bio (QTTB) Q2 Loss Drops 45%

9 months ago - By: Benzinga - Mentions: CMCO DVAX PLYA FLNC

This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

3 months ago - By: Q32 Bio

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

3 months ago - By: Benzinga - Mentions: BFLY EPIX CSCI MOLN ...

12 Health Care Stocks Moving In Monday's After-Market Session

5 months ago - By: Q32 Bio

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

7 months ago - By: Q32 Bio

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

7 months ago - By: Stocktwits

Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug

7 months ago - By: Q32 Bio

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

7 months ago - By: Q32 Bio

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

9 months ago - By: Q32 Bio

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

9 months ago - By: Q32 Bio

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

9 months ago - By: Q32 Bio

Q32 Bio to Participate in Upcoming March Investor Conferences

9 months ago - By: Q32 Bio

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

10 months ago - By: Q32 Bio

Q32 BIO INC (QTTB) Stock News

QTTB Latest News, Press Relases and Analysis

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio (QTTB) Q2 Loss Drops 45%

This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

12 Health Care Stocks Moving In Monday's After-Market Session

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference